Sanofi

SAN

FR0000120578

Pharmaceuticals

Real-time Euronext Paris Other stock markets 03:07:03 2024-04-25 am EDT			5-day change	1st Jan Change
89 ^EUR	+1.48%		+4.42%	-0.85%

08:50am	Sanofi: quarterly EPS down by more than 7% at TCC	CF
08:38am	Wall Street: a note of weakness ahead of US GDP figures	CF

SANOFI : Sell rating from Deutsche Bank

October 26, 2021 at 09:28 am EDT

Emmanuel Papadakis from Deutsche Bank retains his negative opinion on the stock with a Sell rating. The target price is unchanged and still at EUR 80.

Latest news about Sanofi

Sanofi: quarterly EPS down by more than 7% at TCC	02:50am	CF
Wall Street: a note of weakness ahead of US GDP figures	02:38am	CF
Sanofi Posts Lower Q1 Net Income; Net Sales Up	02:19am	MT
Sanofi Sales, Profit Beat Expectations	01:57am	DJ
Sanofi Q1 profit slips on generic competition, forex effects	01:30am	RE
EMEA Morning Briefing : Shares Seen Lower; Earnings, U.S. GDP Data in Focus	12:16am	DJ
SANOFI : Bernstein remains its Buy rating	Apr. 24	ZD
Sanofi to Enlist Banks for $20 Billion Consumer-health Spinoff	Apr. 24	MT
Sector Update: Health Care Stocks Rise Late Afternoon	Apr. 23	MT
Sector Update: Health Care	Apr. 23	MT
Sanofi Asks Banks to Pitch for Roles on Separation of Consumer Health Care Business	Apr. 23	MT
Sanofi Is Said To Ask Banks To Pitch For $20 Billion OTC Spinoff - Bloomberg News	Apr. 23	RE
CAC40: up sharply, back over 8100 pts	Apr. 23	CF
CAC40: back to 8100, E-Stoxx to 5000, Nasdaq +1.5	Apr. 23	CF
CAC40: closes in on 8,100, well supported by W-Street	Apr. 23	CF
CAC40: up slightly after encouraging PMI figures	Apr. 23	CF
Sanofi: positive phase III data in IPT	Apr. 23	CF
Sanofi Reports Positive Results from Phase 3 Trial of Rilzabrutinib for Immune Thrombocytopenia	Apr. 23	MT
Sanofi Says Blood-Disorder Drug Meets Key Target in Late-Stage Trial	Apr. 23	DJ
Sanofi Reaches $100 Million Settlement for US Lawsuits Over Zantac Cancer Claims	Apr. 23	MT
Sector Update: Health Care Stocks Rise in Monday Afternoon Trading	Apr. 22	MT
European Equities Close Higher in Monday Trading; EC Probes TikTok Over Possible DSA Violations	Apr. 22	MT
Top Midday Stories: Verizon Shares Down, Truist Shares Up Post Earnings; CNH Industrial Names New Chief Executive; Tesla Dissolves Newly Created Marketing Team	Apr. 22	MT
Sanofi to Pay More Than $100 Million to Settle 4,000 Suits Alleging Zantac Causes Cancer	Apr. 22	MT
Sanofi Reportedly Agrees to Settle Zantac Cancer Lawsuits for More Than $100 Million	Apr. 22	MT

Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).

Sector

Pharmaceuticals

Calendar

01:30am - Q1 2024 Earnings Release

Related indices

CAC 40 , EURO STOXX 50 , STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

SANOFI : Looking beyond the quarterly miss, Sanofi remains an attractive bet

February 01, 2024 at 11:26 am EST

Sanofi Sees Trend for Years of Steady Growth: CFO

February 03, 2023 at 03:56 pm EST

More Strategies

Ratings for Sanofi

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

87.7 EUR

Average target price

107.8 EUR

Spread / Average Target

+22.87%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SANOFI	-0.85%	117B
ELI LILLY AND COMPANY	+25.61%	660B
NOVO NORDISK A/S	+25.87%	562B
JOHNSON & JOHNSON	-5.24%	358B
MERCK & CO., INC.	+16.49%	322B
ABBVIE INC.	+8.28%	297B
ASTRAZENECA PLC	+7.09%	219B
ROCHE HOLDING AG	-9.12%	196B
NOVARTIS AG	+5.01%	199B
PFIZER, INC.	-8.75%	149B

Other Pharmaceuticals

Sanofi

Equities

SAN

FR0000120578

Pharmaceuticals

SANOFI : Sell rating from Deutsche Bank

Latest news about Sanofi

Chart Sanofi

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Sanofi

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals